Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ruxolitinib Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 29,201Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1092939-17-7, Jakafi, (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, Jakavi, Ruxolitinib (phosphate), Ruxolitinib monophosphate
    Molecular Formula
    C17H21N6O4P
    Molecular Weight
    404.4  g/mol
    InChI Key
    JFMWPOCYMYGEDM-XFULWGLBSA-N
    FDA UNII
    436LRU32H5
    Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
    2.1.2 InChI
    InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
    2.1.3 InChI Key
    JFMWPOCYMYGEDM-XFULWGLBSA-N
    2.1.4 Canonical SMILES
    C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
    2.1.5 Isomeric SMILES
    C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    436LRU32H5
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile

    2. Inc-424

    3. Inc424

    4. Inca24

    5. Incb-018424

    6. Incb-018424 Phosphate

    7. Incb-018424 Salt

    8. Incb-18424

    9. Incb-18424 Phosphate

    10. Incb018424

    11. Incb018424 Phosphate

    12. Jakafi

    13. Jakavi

    14. Opzelura

    15. Ruxolitinib

    16. Ruxolitinib (as Phosphate)

    17. Ruxolitinib Monophosphate

    2.3.2 Depositor-Supplied Synonyms

    1. 1092939-17-7

    2. Jakafi

    3. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Phosphate

    4. Jakavi

    5. Ruxolitinib (phosphate)

    6. Ruxolitinib Monophosphate

    7. Incb018424 Phosphate

    8. Ruxolitinib (as Phosphate)

    9. Incb-018424 Phosphate

    10. Incb-018424 Salt

    11. Ruxolitinib Phosphate [usan]

    12. Incb-18424 Phosphate

    13. Incb018424 Salt

    14. Chebi:66917

    15. 436lru32h5

    16. 1092939-17-7 (phosphate)

    17. (betar)-beta-cyclopentyl-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazole-1-propanenitrile Phosphate

    18. Incb-18424

    19. Ruxolitinib Phosphate Salt

    20. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile Phosphate

    21. (3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)

    22. Phosphenoperoxoic Acid Compound With (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)- 1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile And Dihydrogen (1:1:1)

    23. Opzelura

    24. Unii-436lru32h5

    25. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrilephosphoricacid

    26. Jakafi (tn)

    27. Jakavi (tn)

    28. Ruxolitinib Phosphate(incb018424)

    29. Inc 424 Phosphate

    30. Incb 018424 Phosphate

    31. Incb-424

    32. Schembl1369365

    33. Chembl1795071

    34. Amy5620

    35. Dtxsid00911086

    36. Ruxolitinib Phosphate (jan/usan)

    37. Ruxolitinib Phosphate [mi]

    38. Ruxolitinib Phosphate [jan]

    39. Ex-a2660

    40. Cs1956

    41. Mfcd18452860

    42. S5243

    43. Akos024464417

    44. Ruxolitinib (incb-18424) Phosphate

    45. Ruxolitinib Phosphate [who-dd]

    46. Bcp9000783

    47. Ccg-268687

    48. Cs-0326

    49. 1h-pyrazole-1-propanenitrile, Beta-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betar)-, Phosphate (1:1)

    50. Ac-30901

    51. As-74723

    52. Hy-50858

    53. Ruxolitinib Phosphate [orange Book]

    54. Ruxolitinib (as Phosphate) [ema Epar]

    55. D09960

    56. J-501793

    57. Q27135517

    58. (3r)-3-cyclopentyl-3-(4-{7h-pyrrolo[2,3-d]pyrimidin-4-yl}-1h-pyrazol-1-yl)propanenitrile; Phosphoric Acid

    59. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric Acid

    60. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate

    61. 1h-pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(.beta.r)-,phosphate (1:1)

    62. Phosphoric Acid--3-cyclopentyl-3-[4-(1h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile (1/1)

    2.4 Create Date
    2009-01-19
    3 Chemical and Physical Properties
    Molecular Weight 404.4 g/mol
    Molecular Formula C17H21N6O4P
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count4
    Exact Mass404.13619017 g/mol
    Monoisotopic Mass404.13619017 g/mol
    Topological Polar Surface Area161 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity503
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameJakafi
    PubMed HealthRuxolitinib (By mouth)
    Drug ClassesAntineoplastic Agent
    Active IngredientRuxolitinib phosphate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
    Market StatusPrescription
    CompanyIncyte

    2 of 2  
    Drug NameJakafi
    PubMed HealthRuxolitinib (By mouth)
    Drug ClassesAntineoplastic Agent
    Active IngredientRuxolitinib phosphate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
    Market StatusPrescription
    CompanyIncyte

    4.2 Drug Indication

    * Myelofibrosis (MF):

    Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

    * Polycythaemia vera (PV):

    Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

    * Graft versus host disease (GvHD):

    Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5. 1).

    Treatment of chronic Graft versus Host Disease (cGvHD)

    Treatment of acute graft-versus-host disease (aGvHD)

    Treatment of vitiligo

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EJ01